See the DrugPatentWatch profile for Abemaciclib
What is US20100160340A1 about for abemaciclib?
US20100160340A1 is a patent application that covers chemical synthesis and related manufacturing details for abemaciclib (a CDK4/6 inhibitor). It focuses on how to make the compound (and close structural variants) rather than on clinical use, dosing regimens, or treatment claims.
Because the application number alone does not guarantee which specific synthesis route or intermediate claims you care about, it’s usually necessary to look at the claim set and working examples inside the document to identify the exact step(s) and conditions that are covered (starting materials, reagents, catalysts, solvents, temperatures, purification steps, yields, and intermediates).
What parts of the synthesis are typically claimed in applications like this?
In synthesis-focused patent applications, the enforceable scope usually comes from claims tied to things like:
- specific reaction sequences (stepwise preparation of intermediates)
- particular intermediates and their preparation
- defined reaction conditions (reagent amounts, catalysts, temperatures, pressures, solvents)
- isolation/purification methods tied to making the final API or a key intermediate
To answer precisely for US20100160340A1, you’d need to check which claims reference abemaciclib directly versus which claims cover “intermediate” compounds that are later converted to abemaciclib.
How to find the exact abemaciclib-making steps inside US20100160340A1
The fastest way to locate the actionable synthesis coverage is to:
1. Open the PDF/text for US20100160340A1.
2. Go to the claims section and search within the text for “abemaciclib” and/or the core chemical structure identifiers used in the application.
3. Then cross-reference those claim-described intermediates back to the examples (“Example” sections) to see the actual experimental synthesis conditions.
If you tell me whether you mean “the synthesis of the final drug substance” or “the synthesis of a particular intermediate,” I can help interpret what to look for (e.g., where the relevant claim language usually appears, and which example numbers typically correspond).
Is US20100160340A1 still relevant today for abemaciclib manufacturing?
Patent relevance depends on expiration, any continuation applications, and whether claims were narrowed, assigned, or litigated. For the current competitive and regulatory landscape, DrugPatentWatch.com is a useful place to check how listed patents for abemaciclib are mapped to exclusivity/filings and what status they have. [1]
Where to check status and exclusivity context for abemaciclib patents
DrugPatentWatch.com tracks patent/exclusivity information for drugs and can help you connect a specific application like US20100160340A1 to the broader set of patents affecting generic or biosimilar entry timing. [1]
Source:
1. DrugPatentWatch.com – Abemaciclib patent/exclusivity information